Stockscreener 앱 받기
4.17
8.88%
0.34
시간 외 거래:
4.19
0.02
+0.48%
전일 마감가:
$3.83
열려 있는:
$3.97
하루 거래량:
1.55M
Relative Volume:
0.47
시가총액:
$475.10M
수익:
$884.00K
순이익/손실:
$-103.64M
주가수익비율:
-2.9905
EPS:
-1.3944
순현금흐름:
$-95.45M
1주 성능:
-2.80%
1개월 성능:
-22.78%
6개월 성능:
+21.57%
1년 성능:
+95.77%
1일 변동 폭
$3.97
$4.29
1주일 범위
$3.81
$4.60
52주 변동 폭
$1.60
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
명칭
Perspective Therapeutics Inc
전화
509-375-1202
주소
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
4.17 | 436.37M | 884.00K | -103.64M | -95.45M | -1.3944 |
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | Piper Sandler | Overweight |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-10-10 | 개시 | BTIG Research | Buy |
| 2025-03-13 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-01 | 개시 | Wedbush | Outperform |
| 2024-09-25 | 개시 | Truist | Buy |
| 2024-07-25 | 개시 | BofA Securities | Buy |
| 2024-05-09 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
Aug Analyst Calls: What is the next catalyst for Perspective Therapeutics IncGlobal Markets & Advanced Technical Analysis Signals - baoquankhu1.vn
Perspective Therapeutics Q1 EPS Raised by HC Wainwright - MarketBeat
CATX Technical Analysis | Trend, Signals & Chart Patterns | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Investment Recap: What is the next catalyst for Perspective Therapeutics IncMarket Growth Report & Risk Controlled Daily Plans - baoquankhu1.vn
H.C. Wainwright raises Perspective Therapeutics price target to $13 By Investing.com - Investing.com South Africa
CATX: HC Wainwright & Co. Raises Price Target to $13, Maintains Buy Rating | CATX Stock News - GuruFocus
H.C. Wainwright raises Perspective Therapeutics price target to $13 - Investing.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $13.00 Price Target at HC Wainwright - MarketBeat
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
If You Invested $1,000 in Perspective Therapeutics Inc (CATX) - Stock Titan
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
CATX Should I Buy - Intellectia AI
Perspective Therapeutics Q1 EPS Boosted by Brookline Cap M - MarketBeat
Jones Trading reiterates Perspective Therapeutics stock Buy rating By Investing.com - Investing.com Australia
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Jones Trading reiterates Perspective Therapeutics stock Buy rating - Investing.com
Perspective Therapeutics (CATX) Receives Analyst Rating Boost | CATX Stock News - GuruFocus
B. Riley Financial Issues Positive Forecast for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price - MarketBeat
Perspective Therapeutics (CATX) Receives Analyst Rating Boost | - GuruFocus
Perspective Therapeutics (CATX) Receives Boost from UBS with Rai - GuruFocus
Perspective Therapeutics price target raised to $13 from $11 at B. Riley - TipRanks
UBS Adjusts Price Target on Perspective Therapeutics to $8 From $7, Maintains Buy Rating - marketscreener.com
UBS Group Forecasts Strong Price Appreciation for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock - MarketBeat
Perspective Therapeutics (CATX) Rating Reiterated by Wedbush | C - GuruFocus
Perspective Therapeutics (NYSEAMERICAN:CATX) Receives Outperform Rating from Wedbush - MarketBeat
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT) - The Globe and Mail
B. Riley Raises Price Target on Perspective Therapeutics to $13 From $11, Keeps Buy Rating - marketscreener.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026 - The Manila Times
Perspective Therapeutics (CATX) to Release Earnings on Wednesday - MarketBeat
RBC cuts Perspective Therapeutics stock price target on model updates By Investing.com - Investing.com Australia
Perspective Therapeutics Q4 2025 earnings preview - MSN
Truist reiterates Buy on Perspective Therapeutics stock By Investing.com - Investing.com Canada
BTIG Reiterates Buy Rating for CATX with $14 Price Target | CATX Stock News - GuruFocus
Royal Bank Of Canada Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $14.00 - MarketBeat
RBC Capital Lowers Price Target for CATX While Maintaining 'Outp - GuruFocus
Truist reiterates Buy on Perspective Therapeutics stock - Investing.com
RBC cuts Perspective Therapeutics stock price target on model updates - Investing.com
Perspective Therapeutics stock rating reiterated at Buy by BTIG - Investing.com South Africa
Oppenheimer reiterates Perspective Therapeutics stock rating at Outperform By Investing.com - Investing.com South Africa
Oppenheimer reiterates Perspective Therapeutics stock rating at Outperform - Investing.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Receives "Buy" Rating from BTIG Research - MarketBeat
RBC Cuts Price Target on Perspective Therapeutics to $14 From $18, Keeps Outperform, Speculative Risk - marketscreener.com
Perspective Therapeutics, Inc. 2025 10-K Report: Advancing Targeted Alpha Therapy Radiopharmaceuticals for Cancer Treatment - minichart.com.sg
Perspective Therapeutics Inc (CATX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.03%
자본화:
|
볼륨(24시간):